Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vitae Pharmaceuticals
Fort Washington, Pennsylvania, United Statesvitaepharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Vitae advanced several novel small molecules to Phase 2, including VTP-38543 for atopic dermatitis (topical LXRβ agonist), VTP-43742 for autoimmune/dermatological indications, VTP-201227 for psoriasis (enzyme inhibitor), and VTP-195183 for oncology (nuclear receptor agonist to mobilize progenitor cells); all showed early favorable safety/tolerability in phase 1 and initial phase 2 proof-of-concept studies
- Therapeutic areas
- ImmunologyEndocrinologyNephrologyDermatologyCardiovascularOncologyNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
GlaxoSmithKline
Beyond the preview
Go deeper on Vitae Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vitae Pharmaceuticals.